

# Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2020

<https://marketpublishers.com/r/I6D3675045CEN.html>

Date: February 2020

Pages: 156

Price: US\$ 2,000.00 (Single User License)

ID: I6D3675045CEN

## Abstracts

Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2020, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also

reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 7, 7, 1, 17 and 4 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 4 and 3 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Influenza A Virus, H3N2

Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Influenza A Virus, H3N2 Subtype Infections - Overview

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development

Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment

Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics  
Development

Influenza A Virus, H3N2 Subtype Infections - Drug Profiles

Influenza A Virus, H3N2 Subtype Infections - Dormant Projects

Influenza A Virus, H3N2 Subtype Infections - Discontinued Products

Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Pipeline by Alla Chem LLC, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Pipeline by Allergy Therapeutics Plc, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Pipeline by Ansun Biopharma Inc, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2020

Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020

Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020

Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

AbbVie Inc

Adimmune Corp

Alla Chem LLC

Allergy Therapeutics Plc

Ansun Biopharma Inc

Aphios Corp

Asavi Llc

AstraZeneca Plc

AusBio Ltd

BiondVax Pharmaceuticals Ltd

BlueWillow Biologics Inc

Brandenburg Antiinfektiva GmbH

Changchun Bcht Biotechnology Co Ltd

Chicago Biosolutions Inc

Cidara Therapeutics Inc

Emergent BioSolutions Inc

FluGen Inc

Gamma Vaccines Pty Ltd

i2 Pharmaceuticals Inc

ILiAD Biotechnologies LLC

Inovio Pharmaceuticals Inc  
InvVax Inc  
Jiangsu Kanion Pharmaceutical Co Ltd  
Johnson & Johnson  
Medicago Inc  
NanoViricides Inc  
New Amsterdam Sciences Inc  
Novavax Inc  
PrEP Biopharm Ltd  
Sanofi Pasteur SA  
Sciogen Inc  
Seqirus Ltd  
Serum Institute of India Ltd  
Vacthera BioTech GmbH



## I would like to order

Product name: Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/l6D3675045CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l6D3675045CEN.html>